PCM
CORT icon

Prelude Capital Management’s Corcept Therapeutics CORT Stock Holding History

Prelude Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,466
Closed -$538K – 1275
2025
Q4 		$538K Buy
+15,466
New +$1.21M 0.04% 502
2025
Q2 		– Sell
-14,744
Closed -$1.68M – 1052
2025
Q1 		$1.68M Buy
+14,744
New +$897K 0.13% 181
2020
Q3 		– Sell
-5,978
Closed -$101K – 1903
2020
Q2 		$101K Buy
5,978
+2,059
+53% +$28.9K 0.01% 955
2020
Q1 		$47K Sell
3,919
-5,964
-60% -$73.8K ﹤0.01% 774
2019
Q4 		$120K Buy
+9,883
New +$138K ﹤0.01% 1031
2019
Q3 		– Sell
-4,100
Closed -$46K – 1752
2019
Q2 		$46K Buy
4,100
+2,500
+156% +$27.9K ﹤0.01% 1131
2019
Q1 		$19K Sell
1,600
-75,906
-98% -$943K ﹤0.01% 1320
2018
Q4 		$1.03M Buy
77,506
+20,737
+37% +$274K 0.07% 311
2018
Q3 		$796K Sell
56,769
-1,000
-2% -$14K 0.05% 415
2018
Q2 		$908K Buy
57,769
+1,000
+2% +$17.4K 0.06% 355
2018
Q1 		$934K Buy
56,769
+4,968
+10% +$92.1K 0.07% 296
2017
Q4 		$936K Buy
51,801
+19,452
+60% +$352K 0.08% 267
2017
Q3 		$624K Buy
32,349
+19,020
+143% +$284K 0.06% 325
2017
Q2 		$157K Sell
13,329
-4,200
-24% -$45.7K 0.01% 650
2017
Q1 		$192K Sell
17,529
-19,900
-53% -$175K 0.02% 576
2016
Q4 		$272K Buy
+37,429
New +$293K 0.03% 469
2016
Q1 		– Sell
-11,900
Closed -$59K – 1302
2015
Q4 		$59K Hold
11,900
– – 0.01% 1008
2015
Q3 		$45K Buy
+11,900
New +$60.4K 0.01% 1090

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Prelude Capital Management's CORT Position: Q1 2026 in Review

Prelude Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 15,466 shares — an estimated $538K sold.

Prelude Capital Management first reported a position in CORT in Q3 2015 and held it in 18 quarters. The position peaked at $1.68M in Q1 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Prelude Capital Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 15,466 Corcept Therapeutics shares in Q1 2026, an estimated $538K.
  • Prelude Capital Management first reported a position in Corcept Therapeutics in Q3 2015 and held it in 18 quarters.
  • Prelude Capital Management's Corcept Therapeutics position peaked at $1.68M in Q1 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.